La catena delle opzioni mostra i dati chiave delle opzioni azionarie di OKYO Pharma a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per OKYO Pharma..

OKYO Pharma (NASDAQ:OKYO) Azioni, Catena delle Opzioni

OKYO Pharma

OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.

OKYO Pharma Ltd

Piper Sandler analyst Thomas Champion maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Overweight and raises the price target from $54 to $65.

News

Price Target

Analyst Ratings

RBLX

Piper Sandler Maintains Overweight on Roblox, Raises Price Target to $65

TOVX: 67% &#x7C; <a href="https://www.benzinga.com//node/41665409">Theriva Biologics shares are trading higher after the company announced it was selected as a finalist for Merck KGaA's EMEA Advance Biotech Grant.</a>
&nbsp;
TEAM: 21% &#x7C; <a href="https://www.benzinga.com//node/41680189">Atlassian shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 revenue guidance above estimates.</a>
&nbsp;
EOSE: 14% &#x7C; <a href="https://www.benzinga.com//node/41680096">Eos Energy Enterprises shares are trading higher after the company announced it achieved its second set of performance milestones where achieving these results enables an additional $65 million from the delayed draw term loan.</a>

Movers

Trading Ideas

EOSE

TEAM

TOVX

Market-Moving News for November 1st

U.S.-listed Chinese EV startups Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) reported their October delivery numbers on Friday with Li Auto topping the three by a significant margin.
Li Auto Tops The Chart: Li Auto said on Friday that it delivered 51,443 vehicles in October, marking a 27.3% jump in sales year-over-year but a 4% drop from September when it delivered nearly 54,000 vehicles.
The rise in sales, <a href="https://www.benzinga.com/news/earnings/24/10/41647868/li-auto-q3-earnings-24-topline-growth-1-million-deliveries-milestone-q4-revenue-outlook-lags-street">Li Auto said</a>, could be attributed to robust sales across its model lineup. The company also crossed the landmark of delivering over 1 million vehicles cumulatively in October. 
XPeng Mona M03 Deliveries Exceed 10k Units: XPeng&nbsp;also witnessed its deliveries rise in October but couldn't keep up with Li Auto's pace. The company delivered 23,917 vehicles last month, marking an increase of 20% year-over-year and 12% from September.
The Guangzhou-based EV startup said that the company&#8217;s deliveries of the <a href="https://www.benzinga.com/markets/equities/24/07/39618570/xpeng-debuts-mona-series-with-m03-with-official-launch-in-august-report">XPENG MONA M03 </a>hatchback coupe alone exceeded 10,000 units. 
ONVO Spurs Nio Forward: Shanghai-based Nio, meanwhile, delivered 20,976 vehicles in October, including 16,657 NIO brand vehicles and 4,319 <a href="https://www.benzinga.com/markets/equities/24/10/41195060/tesla-rival-nio-accelerates-global-expansion-to-launch-evs-in-middle-east-amid-eu-tariff-concern">ONVO brand vehicles</a>. This marks a near 1% dip from its September delivery numbers and a whopping 30.5% rise from its sales in October 2023.
Deliveries of the first ONVO vehicle &#8211; the ONVO L60 &#8211; commenced in late September, making October the first whole month of sales for the family-oriented EV brand.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41647639/teslas-chinese-rival-byd-outshines-elon-musks-ev-giant-in-quarterly-revenue-for-first-time-since-202" target="_blank" rel="noreferrer noopener">Chinese EV Behemoth BYD Tops Tesla's Revenue For First Time Since 2022 In Q3</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

XPEV

Li Auto Leads The Pack, XPeng, Nio Clock Growth: Here's How October Deliveries Of Chinese EV Startups Stack Up

HSBC analyst Meredith Jensen downgrades Hyatt Hotels (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/H#NYSE">H</a>) from Buy to Hold and announces $156 price target.

Downgrades

HSBC Downgrades Hyatt Hotels to Hold, Announces $156 Price Target

Michael Saylor&#8216;s declaration that &#8220;MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) is the public equity play on Bitcoin maximalism&#8221; aptly defines the company&#8217;s pioneering approach in <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41585530/asias-microstrategy-metaplanet-buys-another-10-4m-in-bitcoin-exceeds-1-000-btc-holdings">corporate Bitcoin holdings</a>.
Saylor highlighted the company&#8217;s strategy in a post on X on Thursday:
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">MicroStrategy is the public equity play on <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a> Maximalism. <a href="https://t.co/96lpcdN5Zi">pic.twitter.com/96lpcdN5Zi</a>
&mdash; Michael Saylor&#x26a1;&#xFE0F; (@saylor) <a href="https://twitter.com/saylor/status/1852116357724475532?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
How MicroStrategy Leverages Bitcoin: MicroStrategy has not only redefined its own treasury strategy but also set a model that other companies are now beginning to emulate.
The firm's Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)-centric approach, producing returns well above the S&amp;P 500, has led to notable shifts in corporate treasury strategies worldwide.
Since MicroStrategy's pivot in 2020, the company has consistently purchased Bitcoin, achieving an annual average return of 44%, significantly higher than the S&amp;P 500&#8217;s 12% <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40776328/microstrategys-bitcoin-strategy-has-outperformed-every-s-p-500-company-and-even-nvidia-sin">during the same period</a>, Saylor told CNBC in a recent interview.
Notably, MicroStrategy's strategy yielded an 825% return, outperforming even Nvidia&#8217;s 821% rise, further showcasing the power of its Bitcoin holdings. 
The firm continues its role as a &#8220;cash cow&#8221; in the software sector while embracing Bitcoin as a primary treasury asset, according to Saylor. 
This dual model allows MicroStrategy to finance Bitcoin acquisitions through securitized instruments like convertible bonds, presenting investors with exposure to Bitcoin at a reduced volatility level.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41667204/what-coin-should-i-buy-binance-founder-changpeng-zhao-shares-anecdotes-from-4-month-prison">&#8216;What Coin Should I Buy?&#8217;—Binance Founder Changpeng Zhao Shares Anecdotes From 4-Month Prison Stint</a>
Who&#8217;s Following The MicroStrategy Apporach: The bold move has stirred interest among other companies, especially as MicroStrategy recently announced its acquisition of 25,889 BTC in Q3, valued at $1.6 billion.
The strategy brought the company's total holdings to 252,220 BTC, worth approximately $18.23 billion, positioning it as a prominent advocate for using Bitcoin as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41646462/michael-saylor-says-bitcoin-remedy-to-fix-unhealthy-balance-sheets-as-microstrategy-unveil">hedge in uncertain economic times.</a> 
Despite the risks associated with Bitcoin's volatility, Saylor emphasized that Bitcoin "fixes the balance sheet," offering liquidity and resilience to a firm's finances. 
MicroStrategy plans to raise an additional $42 billion through equity and debt financing in the coming years to further its Bitcoin acquisitions, reinforcing its belief in Bitcoin's long-term value.
Following MicroStrategy's example, companies like Cathedra Bitcoin (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBTTF#OTC">CBTTF</a>), Metaplanet and Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) have implemented similar Bitcoin-centered approaches.
Cathedra Bitcoin, listed on the TSX Venture Exchange, has transitioned its operations from mining to data management to sustainably increase its Bitcoin holdings. 
Meanwhile, Metaplanet has prioritized Bitcoin growth month-over-month, achieving a 587% stock increase this year, reflecting a shift toward maximizing Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40942247/microstrategys-bitcoin-playbook-is-becoming-a-hit-among-companies-but-theres-a-catch">reserves to enhance shareholder value.</a>
This shift, coined the &#8220;<a href="https://www.benzinga.com/startups/24/10/41434521/tesla-quietly-transfers-765-million-in-bitcoin-putting-musks-cryptocurrency-strategy-under-intense-s">maximize Bitcoin per share</a>&#8221; approach, is becoming a compelling alternative for firms seeking inflation hedges and asset stability.
For those interested in the ongoing impact of this strategy on the digital finance landscape, Benzinga's <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> event on Nov. 19 will be a pivotal platform to explore further, with discussions on corporate adoption and innovations in digital assets expected.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41662414/donald-trump-wishes-bitcoiners-happy-birthday-vows-to-end-kamalas-war-on-crypto-as-world-l">Donald Trump Wishes Bitcoiners &#8216;Happy Birthday&#8217;, Vows To &#8216;End Kamala&#8217;s War On Crypto&#8217; As World Liberty Financial Falls Way Short Of Fundraising Goal</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

CBTTF

MSTR

SMLR

Michael Saylor Calls MicroStrategy The 'Public Equity Play On Bitcoin Maximalism': Here's Who's Following This Approach

Dividends
Today, Simon&#39;s Board of Directors declared a quarterly common stock dividend of $2.10 for the fourth quarter of 2024. &nbsp;This is an increase of $0.20, or 10.5% year-over-year.&nbsp; The dividend will be payable on December 30, 2024 to shareholders of record on December 9, 2024.&nbsp;
Simon&#39;s Board of Directors declared the quarterly dividend on its 8 3/8% Series J Cumulative Redeemable Preferred Stock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPGPRJ#NYSE">SPGPRJ</a>) of $1.046875 per share, payable on December 30, 2024 to shareholders of record on December 16, 2024.&nbsp;

Dividends

SPGPRJ

Simon Property Group Increases Quarterly Dividend From $2.05 To $2.10 Per Share

Arbor Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABR#NYSE">ABR</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. This is a 21.82 percent decrease over earnings of $0.55 per share from the same period last year. The company reported quarterly sales of $88.81 million which beat the analyst consensus estimate of $83.92 million by 5.82 percent. This is a 17.23 percent decrease over sales of $107.29 million the same period last year.

Earnings

Earnings Beats

Arbor Realty Trust Q3 2024 Adj EPS $0.43 Beats $0.39 Estimate, Sales $88.81M Beat $83.92M Estimate

Brings Extensive Deal-Making And Strategic Experience, Including $700M Licensing Deal With Dr. Reddy's Lab; Highlights Potential Benefits Of Low-Dose Interleukin-2 In Alzheimer's Phase 2 Trial

Management

COYA

Coya Therapeutics Appoints Arun Swaminathan, Ph.D., As CEO

Contracts

CLSK

Canaan To Provide CleanSpark With 3800 Avalon A1566I Immersion Cooling Miners; Financial Details Not Disclosed

Biotech

General

Novo Nordisk's Semaglutide 2.4 mg Achieves Primary Endpoints In Essence Trial, Showing Significant Improvement In Liver Fibrosis And MASH Resolution At Week 72 With Positive Safety Profile; Regulatory Filings Planned For U.S. And EU In 1H 2025, With Detailed Results To Be Presented This Year And Part 2 Readout Expected In 2029

TD Cowen analyst John Blackledge maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $230 to $240.

AMZN

TD Cowen Maintains Buy on Amazon.com, Raises Price Target to $240

Financing

FCEL

FuelCell Energy Closes On Project Debt Financing Transaction With EXIM For Gyeonggi Green Energy Projects; Co. To Receive ~$9.4M In Debt Financing

Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and maintains $300 price target.

ALNY

Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target

WIIM

BFLY

Butterfly Network shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

TILE

Interface shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 net sales guidance above estimates.

Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>), is delighted to announce the appointment of Rúben Amorim as Head Coach of the men's first team, subject to work visa requirements.
He will join until June 2027 with a club option of an additional year once he has fulfilled his obligations to his current club. He will join Manchester United on Monday 11 November.
Rúben is one of the most exciting and highly rated young coaches in European football. Highly decorated as both a player and coach, his titles include winning the Primeira Liga twice in Portugal with Sporting CP; the first of which was the club's first title in 19 years.
Ruud van Nistelrooy will continue to take charge of the team until Rúben joins.

MANU

Manchester United Announces The Appointment Of Rúben Amorim As Head Coach; Ruud Van Nistelrooy Will Continue To Take Charge Of The Team Until Rúben Joins

TD Cowen analyst Gautam Khanna downgrades Huntington Ingalls Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>) from Buy to Hold and announces $180 price target.

TD Cowen Downgrades Huntington Ingalls Indus to Hold, Announces $180 Price Target

<h3>Gainers</h3>
<ul>
<li>Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) shares rose 15.0% to $49.25 during Friday's pre-market session. The market value of their outstanding shares is at $6.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares rose 14.56% to $0.52. The market value of their outstanding shares is at $19.3 million. The company's, Q2 earnings came out yesterday. </li>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) stock moved upwards by 7.6% to $0.75. The market value of their outstanding shares is at $18.3 million. </li>
<li>Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) stock moved upwards by 7.29% to $199.99. The company's market cap stands at $2.0 trillion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) shares rose 7.0% to $0.81. The market value of their outstanding shares is at $70.3 million. </li>
<li>Tokyo Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) shares moved upwards by 6.08% to $0.48. The company's market cap stands at $20.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Visionary Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) stock decreased by 12.9% to $1.08 during Friday's pre-market session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares declined by 11.26% to $1.42. The company's market cap stands at $4.0 million. </li>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) stock fell 8.49% to $1.51. The company's market cap stands at $9.8 million. </li>
<li>Lead Real Estate Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRE#NASDAQ">LRE</a>) shares declined by 6.96% to $2.14. The market value of their outstanding shares is at $29.1 million. </li>
<li>BJ's Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) stock declined by 5.67% to $34.99. The company's market cap stands at $810.1 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>J-Long Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JL#NASDAQ">JL</a>) shares fell 5.6% to $0.54. The company's market cap stands at $16.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMBO

BJRI

FLYE

GOEV

HOFV

TKLF

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) shares moved upwards by 15.0% to $49.25 during Friday's pre-market session. The market value of their outstanding shares is at $6.0 billion. As per the press release, Q3 earnings came out today. </li>
<li>Phoenix Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEV#NASDAQ">PEV</a>) shares moved upwards by 14.56% to $0.52. The market value of their outstanding shares is at $19.3 million. The company's, Q2 earnings came out yesterday. </li>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares rose 7.6% to $0.75. The market value of their outstanding shares is at $18.3 million. </li>
<li>Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) stock rose 7.29% to $199.99. The market value of their outstanding shares is at $2.0 trillion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Canoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOEV#NASDAQ">GOEV</a>) stock rose 7.0% to $0.81. The market value of their outstanding shares is at $70.3 million. </li>
<li>Tokyo Lifestyle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) stock rose 6.08% to $0.48. The market value of their outstanding shares is at $20.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Visionary Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) shares declined by 12.9% to $1.08 during Friday's pre-market session. The company's market cap stands at $4.0 million. </li>
<li>Ambow Education Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMBO#AMEX">AMBO</a>) shares fell 11.26% to $1.42. The market value of their outstanding shares is at $4.0 million. </li>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) shares fell 8.49% to $1.51. The market value of their outstanding shares is at $9.8 million. </li>
<li>Lead Real Estate Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRE#NASDAQ">LRE</a>) shares declined by 6.96% to $2.14. The market value of their outstanding shares is at $29.1 million. </li>
<li>BJ's Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) stock decreased by 5.67% to $34.99. The company's market cap stands at $810.1 million. The company's, Q3 earnings came out yesterday. </li>
<li>J-Long Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JL#NASDAQ">JL</a>) stock fell 5.6% to $0.54. The company's market cap stands at $16.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

<h3>Gainers</h3>
<ul>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) stock moved upwards by 66.0% to $4.4 during Friday's pre-market session. The market value of their outstanding shares is at $86.8 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares increased by 43.83% to $2.1. The company's market cap stands at $2.8 million. </li>
<li>Athira Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHA#NASDAQ">ATHA</a>) stock increased by 26.13% to $0.54. The company's market cap stands at $20.6 million. </li>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock moved upwards by 18.06% to $36.62. The market value of their outstanding shares is at $122.9 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 16.79% to $6.26. The company's market cap stands at $230.5 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares increased by 16.04% to $4.05. The company's market cap stands at $307.5 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) stock decreased by 39.5% to $1.18 during Friday's pre-market session. The market value of their outstanding shares is at $426.5 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 10.37% to $0.77. The market value of their outstanding shares is at $18.3 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares declined by 9.76% to $1.11. The market value of their outstanding shares is at $6.1 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares fell 9.1% to $1.6. The company's market cap stands at $15.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock fell 9.1% to $1.3. The market value of their outstanding shares is at $20.1 million. </li>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock declined by 8.07% to $0.57. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATHA

BFRI

BIAF

CDXC

Envoy Medical, Inc. - Class A Common Stock

COCH

LXRX

MOLN

MTNB

ONMD

PDEX

TRIB

12 Health Care Stocks Moving In Friday's Pre-Market Session

Warning: OKYO is at high risk of performing badly

OKYO Pharma (OKYO) announces that the first patient has been dosed in the Phase 2 trial of topical ocular OK-101 to treat NCP. The Phase 2 study is...

Okyo Pharma announces first patient dosed in Phase 2 trial of OK-101

OKYO

Press Releases

OKYO Pharma Announces Chairman Acquires Shares

Health Care

OKYO Pharma CEO Interview to Air on Bloomberg TV

OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Legal

OKYO Pharma Granted U.S. Patent Covering OK-101's Potential for Treating Symptoms of Dry Eye Disease

OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference

Comments

OKYO Pharma

OKYO Pharma (OKYO) Opzioni

Loading...

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO